UNION CITY, Calif., Aug. 12, 2008 (PRIME NEWSWIRE) -- Questcor Pharmaceuticals, Inc. (Nasdaq:QCOR) announced today it will present at the upcoming 4th Annual Summer Technology Conference hosted by Security Research Associates, Inc. The conference will be held on Monday, August 18, 2008 at the Omni Hotel in San Francisco. Dave Medeiros, Senior Vice President of Pharmaceutical Operations and Eldon Mayer, Vice President of Commercial Operations will discuss the Company's business strategy and historical financial performance at 3:00 p.m. Pacific Time on Monday, August 18th.
About Questcor
Questcor Pharmaceuticals, Inc. is a pharmaceutical company that markets two commercial products, H.P. Acthar(r) Gel ("Acthar") and Doral(r). Acthar (repository corticotropin injection) is an injectable drug that is approved for the treatment of certain disorders with an inflammatory component, including the treatment of exacerbations associated with multiple sclerosis ("MS"). In addition, Acthar is not indicated for, but is used in treating patients with infantile spasms ("IS"), a rare form of refractory childhood epilepsy, and opsoclonus myoclonus syndrome, a rare autoimmune-related childhood neurological disorder. Doral is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. The Company is also developing QSC-001, a unique orally disintegrating tablet formulation of hydrocodone bitartrate and acetaminophen for the treatment of moderate to moderately severe pain. For more information, please visit www.questcor.com.